CYT
- Cyteir Therapeutics, Inc.
()
Overview
Company Summary
Cyteir Therapeutics, Inc. (CYT) is a biotechnology company that specializes in developing innovative treatments for cancer. The company's primary focus is on developing targeted therapies aimed at enhancing the DNA repair process in cancer cells. By leveraging advancements in synthetic lethal interactions, Cyteir aims to disrupt cancer cell survival mechanisms while minimizing damage to healthy cells.
One of Cyteir's core technologies is the use of synthetic lethality, which exploits specific genetic vulnerabilities in cancer cells. This approach allows the company to selectively target and eliminate cancerous cells while sparing healthy cells. By understanding the molecular drivers of DNA repair and cell cycle control, Cyteir is able to identify potential drug targets that can be inhibited to disrupt tumor growth.
The company's lead program, CYT-0851, is a highly selective small molecule inhibitor that targets RAD51, an essential protein involved in DNA repair. By blocking the action of RAD51, CYT-0851 aims to inhibit the DNA repair process in cancer cells, leading to their destruction. Additionally, Cyteir is actively working on multiple preclinical programs that target different components of the DNA repair pathway, offering a diversified approach to treating various types of cancers.
Cyteir Therapeutics aims to bring its innovative therapies to patients by conducting rigorous preclinical and clinical research, as well as collaborating with academic institutions, industry partners, and regulatory agencies. By focusing on enhancing the DNA repair process of cancer cells, Cyteir strives to make a significant impact in the field of oncology and contribute to the development of more effective and targeted cancer treatments.